Author:
Ishizaki Jun,Hasegawa Hitoshi
Reference24 articles.
1. Cummings SR, Grady D, Hulley SB (2013) Designing a randomized blinding trial. In: Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB (eds) Designing clinical research, 4th edn. Lippincott Williams & Wilkins/Wolters Kluwer Health, Philadelphia
2. den Broeder AA, Verhoef LM, Fransen J et al (2017) Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials 18:403
3. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2016) Guideline for good clinical practice E6 (R2). ICH harmonized tripartite guideline. ICH, Geneva
4. Karsh J, Keystone EC, Haraoui B et al (2011) Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design. J Rheumatol 38:2095–2104
5. Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581